Dogwood Therapeutics, Inc. 8-K

What Happened
Dogwood Therapeutics, Inc. announced that at its annual meeting of stockholders on June 16, 2026, shareholders approved an amendment to the company's Certificate of Incorporation (Proposal 3). The company filed the Certificate of Amendment with the Delaware Secretary of State on June 17, 2026, and the amendment became effective upon filing. The full text of the amendment is attached to the 8-K as Exhibit 3.1.

Key Details

• Stockholder approval occurred at the Annual Meeting on June 16, 2026.
• Certificate of Amendment was filed with the Delaware Secretary of State and became effective on June 17, 2026.
• The full text of the Certificate of Amendment is included as Exhibit 3.1 to the Form 8-K.
• The Form 8-K was signed on behalf of Dogwood Therapeutics by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer, on June 17, 2026.

Why It Matters
A change to the Certificate of Incorporation updates the company’s foundational corporate charter and may affect governance or capital structure depending on the amendment’s content. The 8-K provides the amendment text as Exhibit 3.1, so investors who want to assess potential impacts (on voting rights, authorized shares, anti-takeover provisions, etc.) should review that exhibit for specifics.